Earning Calls

Track latest earnings announcements, revenue performance and access transcripts across competitors.

Amgen

Announced on May 02, 2026

Executive Summary:

Amgen delivered solid Q1 results with continued strength in core therapeutic franchises and disciplined operational execution. Management highlighted progress on biosimilar portfolio expansion and reaffirmed full-year guidance supported by resilient demand across key markets.

Revenue Growth:+5.4% YoY

Operating Income:$2.2B

Operating Margin:29.2%

Key Takeaways:

Biosimilars Expansion
Biosimilar portfolio delivered double-digit growth globally.
International Growth
Strong momentum across Europe and emerging markets.
Strong Product Performance
XGEVA® and Prolia® continued strong demand across key markets.
Cost Discipline
Operational efficiency initiatives supported margin expansion.
Positive Outlook
Management reaffirmed FY2026 guidance and growth expectations.

Future Outlook:

Amgen provided its guidance for FY'26

Total revenue expected in the range of $36.2B–$37.4B, reflecting mid-single-digit growth ex-hedging impacts.
Non-GAAP EPS outlook of $20.55–$21.75 driven by operating leverage and share repurchases.
Capital allocation prioritizes late-stage clinical programs and targeted business development.
Biosimilar contribution modeled to ramp through H2 as new formulations reach major markets.
FX and payer dynamics incorporated conservatively into regional revenue assumptions.